Sol-Gel Technologies (SLGL) has released an update.
Sol-Gel Technologies announced a significant improvement in its financial performance for Q3 2024, with a reduction in net losses and an increase in revenues, driven by new licensing agreements and clinical advancements. The company is actively progressing its Phase 3 trial for SGT-610, targeting the lucrative Gorlin syndrome market, and its SGT-210 proof-of-concept study for Darier disease. Additionally, Sol-Gel has strategically shifted its stock listing within Nasdaq to comply with bid price requirements, ensuring continued trading stability.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
